<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357433</url>
  </required_header>
  <id_info>
    <org_study_id>01-2015_R</org_study_id>
    <nct_id>NCT02357433</nct_id>
  </id_info>
  <brief_title>Mortality Reduction in Septic Shock by Plasma Adsorption</brief_title>
  <acronym>ROMPA</acronym>
  <official_title>Reduccion de la Mortalidad Mediante Plasma-Adsorción en Shock séptico (ROMPA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francisco Colomina Climent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario San Juan de Alicante</source>
  <brief_summary>
    <textblock>
      The study objective is to clarify whether the application of high doses CPFA (Coupled
      Plasma-Filtration Adsorption) in addition to the current clinical practice is able to reduce
      hospital mortality in septic shock patients in intensive care unit (ICU).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Circumstances beyond the course of the trial have produced a change in the conditions of
    recruitment unacceptable to the ROMPA researchers
  </why_stopped>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time resolution of septic shock</measure>
    <time_frame>within the first 28 days</time_frame>
    <description>normalization of lactate, and the decrease in vasoactive drugs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>High doses CPFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): &gt;0.20 L/kg/day of plasma treated in the first 3 days after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Doses CPFA</intervention_name>
    <arm_group_label>High doses CPFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients admitted to the ICU in septic shock

          -  all patients that develop septic shock while in the ICU

        Exclusion Criteria:

          -  Age less than 18 years

          -  Pregnancy

          -  Estimated life expectancy (due to comorbidities) less than 90 days

          -  Presence of relative or absolute contraindications to CPFA

          -  Absence of informed consen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Colomina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de San Juan de Alicante</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Vinalopó</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03293</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Vega Baja</name>
      <address>
        <city>Orihuela</city>
        <state>Alicante</state>
        <zip>03300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de San Juan de Alicante</name>
      <address>
        <city>Sant Joan d'Alacant</city>
        <state>Alicante</state>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Torrevieja</name>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marina Baixa</name>
      <address>
        <city>Villajoyosa</city>
        <state>Alicante</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Plana</name>
      <address>
        <city>Villarreal</city>
        <state>Castellon</state>
        <zip>12540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Santa Lucia</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Frances De Borja de Gandia</name>
      <address>
        <city>Gandia</city>
        <state>Valencia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lluis Alcanyis</name>
      <address>
        <city>Xátiva</city>
        <state>Valencia</state>
        <zip>46800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 23, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario San Juan de Alicante</investigator_affiliation>
    <investigator_full_name>Francisco Colomina Climent</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

